RU2013122123A - Терапевтические средства для улучшения легочной функции - Google Patents
Терапевтические средства для улучшения легочной функции Download PDFInfo
- Publication number
- RU2013122123A RU2013122123A RU2013122123/10A RU2013122123A RU2013122123A RU 2013122123 A RU2013122123 A RU 2013122123A RU 2013122123/10 A RU2013122123/10 A RU 2013122123/10A RU 2013122123 A RU2013122123 A RU 2013122123A RU 2013122123 A RU2013122123 A RU 2013122123A
- Authority
- RU
- Russia
- Prior art keywords
- antagonist
- human
- seq
- composition
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Measuring devices for evaluating the respiratory organs
- A61B5/087—Measuring breath flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5437—IL-13
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Physiology (AREA)
- Surgery (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39367710P | 2010-10-15 | 2010-10-15 | |
| US61/393.677 | 2010-10-15 | ||
| US201161508723P | 2011-07-18 | 2011-07-18 | |
| US61/508.723 | 2011-07-18 | ||
| PCT/EP2011/067947 WO2012049278A1 (en) | 2010-10-15 | 2011-10-14 | Therapies for improving pulmonary function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013122123A true RU2013122123A (ru) | 2014-11-20 |
Family
ID=44800047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013122123/10A RU2013122123A (ru) | 2010-10-15 | 2011-10-14 | Терапевтические средства для улучшения легочной функции |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20130281876A1 (https=) |
| EP (1) | EP2627673B1 (https=) |
| JP (1) | JP2013544235A (https=) |
| CN (1) | CN103328506A (https=) |
| AU (1) | AU2011315499A1 (https=) |
| BR (1) | BR112013009055A2 (https=) |
| CA (1) | CA2814431A1 (https=) |
| DK (1) | DK2627673T3 (https=) |
| ES (1) | ES2645368T3 (https=) |
| HU (1) | HUE034005T2 (https=) |
| MX (1) | MX2013004212A (https=) |
| NO (1) | NO2627673T3 (https=) |
| PL (1) | PL2627673T3 (https=) |
| RU (1) | RU2013122123A (https=) |
| WO (1) | WO2012049278A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9574004B2 (en) | 2012-08-21 | 2017-02-21 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
| WO2015057668A1 (en) * | 2013-10-15 | 2015-04-23 | Medimmune, Llc | Methods for treating chronic obstructive pulmonary disease using benralizumab |
| CA2937387A1 (en) * | 2014-01-27 | 2015-07-30 | Medimmune, Llc | Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung |
| IL315136A (en) * | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| CA2943326A1 (en) | 2014-04-11 | 2015-10-15 | Novartis Ag | Methods of selectively treating asthma using il-13 antagonists |
| AU2016205188A1 (en) | 2015-01-09 | 2017-06-22 | Medimmune, Llc | Assay to detect human DPP-4 |
| CN104605857A (zh) * | 2015-02-12 | 2015-05-13 | 上海朔茂网络科技有限公司 | 一种肺功能测量方法 |
| JP6871948B2 (ja) | 2016-04-27 | 2021-05-19 | アッヴィ・インコーポレイテッド | 抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法 |
| BR112019018022A2 (pt) * | 2017-03-01 | 2020-06-02 | Medimmune Limited | Formulações de anticorpos monoclonais |
| US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| MX2021010560A (es) | 2019-03-06 | 2021-11-12 | Regeneron Pharma | Inhibidores de la via il-4/il-13 para una eficacia aumentada en el tratamiento de cancer. |
| CA3132587A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| BR112022000740A2 (pt) | 2019-07-16 | 2022-07-05 | Sanofi Biotechnology | Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r |
| JP2023536159A (ja) * | 2020-07-31 | 2023-08-23 | ジェネンテック， インコーポレイテッド | 炎症性呼吸器疾患の増悪を治療するための方法 |
| CN112341543B (zh) * | 2021-01-11 | 2021-04-23 | 广东赛尔生物科技有限公司 | 包含间充质干细胞外泌体的药物组合物在治疗疾病中的应用 |
| US20230220089A1 (en) | 2021-12-30 | 2023-07-13 | Regeneron Pharmaceuticals, Inc. | Methods for attenuating atopic march by administering an il-4/il-13 antagonist |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2140660A1 (en) * | 1993-06-13 | 1994-12-22 | Uwe R. Juergens | Use of terpene compounds for reduced release of arachidonic acid and of inflammation mediators |
| GB0004016D0 (en) | 2000-02-22 | 2000-04-12 | Royal Brompton Hospital | Biological material and uses thereof |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| EP1824886B1 (en) * | 2004-11-17 | 2010-12-22 | Amgen Inc. | Fully human monoclonal antibodies to il-13 |
| GB0600488D0 (en) * | 2006-01-11 | 2006-02-22 | Glaxo Group Ltd | Immunoglobulins |
-
2011
- 2011-10-14 WO PCT/EP2011/067947 patent/WO2012049278A1/en not_active Ceased
- 2011-10-14 DK DK11769881.1T patent/DK2627673T3/da active
- 2011-10-14 CN CN2011800498365A patent/CN103328506A/zh active Pending
- 2011-10-14 EP EP11769881.1A patent/EP2627673B1/en not_active Not-in-force
- 2011-10-14 RU RU2013122123/10A patent/RU2013122123A/ru not_active Application Discontinuation
- 2011-10-14 JP JP2013533226A patent/JP2013544235A/ja active Pending
- 2011-10-14 NO NO11769881A patent/NO2627673T3/no unknown
- 2011-10-14 US US13/879,261 patent/US20130281876A1/en not_active Abandoned
- 2011-10-14 ES ES11769881.1T patent/ES2645368T3/es active Active
- 2011-10-14 CA CA2814431A patent/CA2814431A1/en not_active Abandoned
- 2011-10-14 AU AU2011315499A patent/AU2011315499A1/en not_active Abandoned
- 2011-10-14 HU HUE11769881A patent/HUE034005T2/en unknown
- 2011-10-14 MX MX2013004212A patent/MX2013004212A/es unknown
- 2011-10-14 PL PL11769881T patent/PL2627673T3/pl unknown
- 2011-10-14 BR BR112013009055A patent/BR112013009055A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN103328506A (zh) | 2013-09-25 |
| BR112013009055A2 (pt) | 2016-07-19 |
| ES2645368T3 (es) | 2017-12-05 |
| JP2013544235A (ja) | 2013-12-12 |
| PL2627673T3 (pl) | 2018-01-31 |
| EP2627673A1 (en) | 2013-08-21 |
| DK2627673T3 (da) | 2017-11-06 |
| EP2627673B1 (en) | 2017-07-26 |
| HUE034005T2 (en) | 2018-01-29 |
| WO2012049278A1 (en) | 2012-04-19 |
| CA2814431A1 (en) | 2012-04-19 |
| NO2627673T3 (https=) | 2017-12-23 |
| AU2011315499A1 (en) | 2013-05-02 |
| US20130281876A1 (en) | 2013-10-24 |
| MX2013004212A (es) | 2013-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013122123A (ru) | Терапевтические средства для улучшения легочной функции | |
| KR102679182B1 (ko) | Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법 | |
| US10913793B2 (en) | DNA molecules encoding anti-IL-33 antibodies | |
| US8338135B2 (en) | High affinity human antibodies to human IL-4 receptor | |
| US7608693B2 (en) | High affinity human antibodies to human IL-4 receptor | |
| JP2022023051A (ja) | 瘻孔を伴うクローン病の治療用ベドリズマブ | |
| AU2016204960A1 (en) | 4-1BB binding molecules | |
| IL310926B2 (en) | Treatment of chronic obstructive pulmonary disease with anti-interleukin-33 antibody | |
| JP7722991B2 (ja) | 抗ｆｃｒｎ抗体を用いた温熱自己免疫性溶血性貧血の治療方法 | |
| JP2024542777A (ja) | 多発血管炎、好酸球増多症候群、好酸球増多症候群、鼻ポリープを伴う慢性副鼻腔炎（ｃｒｓｗｎｐ）又は鼻ポリープを伴わない慢性副鼻腔炎（ｃｒｓｓｎｐ）の処置における使用のためのインターロイキン５結合タンパク質投与レジメン | |
| AU2022315512A1 (en) | Treatment of anti-pla2r autoantibody-mediated membranous nephropathy | |
| US20250179208A1 (en) | Anti-cd26 antibodies and use thereof | |
| ES3057414T3 (en) | Interleukin 5 binding protein dosage regimen | |
| CN113993543B (zh) | 使用抗cd38抗体的组合疗法 | |
| EP4647084A1 (en) | Method for treating asthma by using tslp antibody | |
| CN118791612A (zh) | 靶向cd26的抗原结合蛋白及其药物应用 | |
| TH1901006538A (th) | การบำบัดโรคหอบหืดด้วยแอนติบอดี้ต้าน tslp | |
| EA050171B1 (ru) | Способы и комбинации для лечения рака с применением антител, являющихся ингибиторами иммунных контрольных точек | |
| IL271284B (en) | Methods of treating or preventing asthma by administering an antagonist to -il-r4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160211 |